Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

HEM TEST 2024 > DLBCL facts > Flashcards

DLBCL facts Flashcards

1
Q

Immunophenotype of DLBCL

A

CD20, CD19, CD79a
GCB- CD10 + , Bcl6 +
Non GCB- CD10-, MUM1 +

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

IPI DLBCL

A

LDH
Age 60
Advanced stage
> 1 extranodal site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

sensitivity of Hans criteria in DLBCL

A

70-80%
should not determine TX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Lymph2Cx assay in DLBCL
LymphoGen

A

Nano-string gene profiling
better sensitivity for subclassification for GCB/non GCB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

ctDNA DLBCL

A

Better in detecting minimal disease than imaging. not clinically available

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Pts with most benefit from pola in DLBCL

A

Age> 60
IPI 3-5
ABC

approved for IPI>1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

CART in 1st line DLBCL

A

R-CHOP lead of 1-2 cycles
High risk pts
ZUMA12 (high IPI, DH or positive interim PET)
ZUMA23 (high risk pts)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tafasitamab in 1st line DLBCL

A

CD19 Ab
Front-MIND
Tafa-len 1st line trial vs RCHOP
Investigational
Result pending

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

2nd line CART in DLBCL

A

Axi-cell (CD28) ZUMA7
OS
Liso-cell (4-1BB)- less toxic TRANSFORM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

CART trials in DLBCL

A

Axi
ZUMA7- 2nd line
bridging with steroids only
OS advantage
ZUMA1- 3rd line

Liso
TRANSFORM- 2nd line
TRANSCEND- 3rd line

Tisa
BELINDA- 2nd line- negative trial
JULIET- 3rd line

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

VH4-34 IgH gene phonotype in DLBCL

A

ABC
poor prognosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Advantage of geriatric assessment in DLBCL

A

Better identifies pts above/below age 80 as fit/unfit/frail

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

X6 RCHOP vs 8X RCHOPin DLBCL

A

GOYA trial
same effectiveness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

GCSF support in RCHOP

A

Primary prophylaxis in age > 6
Or comorbities, prior infections, prior cytopenias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Polatuzumab in 1st line DLBCL

A

6X RCHP + 2XR
vs RCHOP
76% vs 70% 2 year PFS
no OS
advantage in ABC, IPI >3, Age>60
higher rates of febrile neutropenia and peripheral neuropathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Tafa+ Len 1st line in DLBCL

A

L-MIND
2nd-3rd line
compared to len
60% ORR CR 40%
median PFS 12 months
well tolerated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Tafasitamab

A

CD19 Ab

18
Q

DA-EPOCH-R OS in PMBCL

A

nearly 100% long time OS

19
Q

PMBCL subtype

A

Closer to ABC
MUM1+

20
Q

HIV associated DLBCL subtypes

A

mild immunodeficiency- GCB/BL
severe immunodeficiency- ABC

21
Q

HIV associated DLBCL TX

A

DA-EOCH-R
but with much lower doses
specifically for cytoxan
CNS porphylaxis
88% ORR

22
Q

Testicular, leg type and PCNSL immunophenotype

A

MYD-88
PDL-1
PIM1
CD79b

23
Q

Testicular lymphoma Tx

A

Orchiectomy and contralateral RT

24
Q

PCNSL workup

A

tentacular US
Eye exam
BMB
Spinal MRI

25
Q

Luncastuximab Tesirine in DLBCL 3rd line

A

CD19 with chemo attached
single arm in advanced lines
25% CR
PFS 5 months
bridginig?

26
Q

Glofitimab in DLBCL 3rd line

A

2:1
CD20:CD3
IV
8-12 cycles
CR 40%
PFS 5 months

27
Q

Epcoritimab in DLBCL 3rd line

A

1:1
SC
until progression
CR 40%
PFS 5 months

28
Q

Axi-cell 2nd line in DLBCL

A

ZUMA7
bridging with steroids only
pts rapidly progressing were excluded
crossover allowed
CR 65%

29
Q

Tisa-cell 2nd line in DLBCL

A

BELINDA
negative study
bridging therapy allowed
crossover allowed
CR 30%
Long time of production

30
Q

Liso-cell 2nd line in DLBCL

A

TRANSFORM
Salvage allowed
CR 66%
Sorting of CD4 and CD8 in order to give 1:1 ratio
Done in order to reduce toxicity
Less toxic

31
Q

Adriamycin dose adjustments

A

CKD- no need to dose adjust
Liver- reduce to 50% if bili 1-3, 25% if 3-5, don’t adminster if >5

32
Q

Early PTLD definition

A

12-24 months post transplant

33
Q

Late PTLD time of occurrence

A

5-10 post transplant

34
Q

Risk factors for failure of single agent R in mPTLD

A

High IPI
Bulky disease

35
Q

Risk factors for failure of single agent R in mPTLD

A

High IPI
Bulky disease

36
Q

Risk factors for Tx failure in mPTLD

A

Hypoalbuminemia
BM involvement
CNS involvement

37
Q

1st line Tx for PTLD

A

R x4
Escalation to R CHOP
or
R EPOCH if signs of high-risk disease

If PR but with indolent disease- continue weekly R

38
Q

Sequential Tx in PTLD

A

R X4
Followed by CHOP X4

39
Q

PMBCL immunophenotype

A

CD19, CD20, CD22, CD79a positive
Surface immunoglobulin negative
CD30 weak, CD15 negative

40
Q

Management of Deauville 4 (PR) on end of Tx PETCT in PMBCL

A

FU or RT
Deauville 4 may be a sign of inflammation after DA-EPOCH-R and not of disease

41
Q

DLBCL survival by IPI

A

0- 95%
1-2- 80%
>2- 55%

HEM TEST 2024 (32 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions